Role of oral anticoagulants on clinical outcomes in COVID-19 infection: Develop and implement new statistical approaches to evaluate potential relationships and practical implications

Role of oral anticoagulants on clinical outcomes in COVID-19 infection: Develop and implement new statistical approaches to evaluate potential relationships and practical implications.

Since coagulopathy is a common complication of COVID-19, oral anticoagulants (OAC) may play a direct role in COVID-19 pathology, and hence the association between COVID-19 and OAC is of key interest. However, this association appears complex and bi-directional, with increasing susceptibility to the COVID-19 infection or severity, while the mortality of severe COVID-19 is relatively high among people on OAC. Therefore, the specific role of OAC in disease management remains unclear, and the role of concurrent risk factors and variation to medication management need to be considered at individual-level to estimate true impact of OAC on clinical outcomes, and further, to validate the application of anticoagulant in COVID-19.

The project is aimed to (1) Identify the dependence structure between OAC and survival in patients with COVID-19, (2) Compare the adjusted mortality between people on OAC and people not on OACs, (3) Evaluate insights for consideration of OAC in the management of patients with COVID-19, and (4) Disseminate and communicate the findings in most effective manner.

It is expected the successful applicant (s) must commence on or before 1st February 2021.

For any enquiries please contact Dr Ruwanthi Kolamunnage-Dona on [Email Address Removed]

If you wish to apply, please send a covering letter, full CV together with names and contact details of two academic referees, stating the research proposal/s of interest to you and why you think you are suitable. Please send to Dr Ruwanthi Kolamunnage-Dona on [Email Address Removed] and Professor Barr on [Email Address Removed]